PDF
Inhalation Sciences receives new order for innovative new in vivo module from Italian big pharma company Chiesi
(Stockholm, 9 November 2021) The new order, worth 355 000 SEK, is with long-term client Chiesi (Chiesi Farmaceutici S.p.A), a leading company within asthma and COPD. Chiesi has ordered ISAB's new in vivo mouse exposure module. Mice are the preferred test subject for the development of biologic drugs, making ISAB's new high-precision, one-animal-at-a-time module extremely relevant for the growing number of companies currently developing inhaled biologics, rather than traditional small molecule therapies.
ISAB's new mouse exposure module is a new entry into PreciseInhale's extensive suite of exposure modules. The new module offers great flexibility as well as precision to drug developers. It precisely generates controlled aerosol to single animals through either Nose-Only or Intratracheal exposures, generating high-precision data and significantly reducing the need for large numbers of test animals.
Mice are the preferred test subject for the development of biologic drugs, sharing a high degree of homology with humans and enabling researchers to work with an extensive range of disease models. PreciseInhale's new mouse module makes the system even more relevant to the growing number of advanced companies working on inhaled biologics, such as proteins, rather than traditional small molecules.
ISAB CEO Manoush Masarrat: "We're delighted with this new sale to such an innovative and esteemed customer. It really validates our scientific `aerosol switchboard' model - where we offer inhaled drug developers a comprehensive choice of exposure modules - and it brings all the advantages of precision dosing to the highly valuable area of mouse exposures. We're proud and pleased to continue our long, much-valued relationship with Chiesi."